Novartis Pharma AG: Novartis Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials

Results from two parallel trials show Cosentyx (secukinumab) demonstrated superior efficacy vs placebo with statistically significant improvement in hidradenitis suppurativa (HS) signs and symptoms1Safety

Related Keywords

United States ,Italy ,Milan ,Lombardia ,Vinkel ,Nordrhein Westfalen ,Germany ,America ,Isabella Zinck ,Michael Meo ,Dermatol Venereol ,Mac Mahon ,Clin Aesthet Dermatol ,Hidradenitis Suppurativa ,Nicole Zinsli Somm ,Samir Shah ,Parag Mahanti ,Julie Masow ,Todd Fox ,Sloan Simpson ,Chandler Wright ,Alexab Kimball ,Alina Levchuk ,European Academy Of Dermatology ,Global Head Of Medical Affairs Immunology ,National Institute Of Health ,Twitter ,Beth Israel Deaconess Medical Center ,American College Of Rheumatology ,Rare Diseases Information Center ,Intj Environ Res Public Health ,Novartis ,Novartis Europharm ,Virtual Congress ,Harvard Medical School ,Novartis Us External Communications ,Exchange Commission ,European Alliance Of Associations ,Novartis Pharma Communications ,Novartis Pharmaceuticals Corp ,European Academy ,Harvard Medical ,Global Head ,Medical Affairs Immunology ,Hidradenitis Suppurativa Clinical Response ,Numeric Rating Scale ,Health Related Quality ,Patient Reported Outcomes ,Patient Relat Outcome ,Rev Dis ,Two Secukinumab Dose Regimens ,Subjects With Moderate ,Severe Hidradenitis Suppurativa ,Hidradenitis Suppurativa Signs ,Systematic Review ,Intj Environ Res Public ,Provides Sustained Improvements ,Psoriatic Arthritis ,Pooled Safety ,Enthesitis Related Arthritis ,Juvenile Psoriatic Arthritis ,Primary Results ,Treatment Withdrawal ,European Alliance ,Associations For Rheumatology ,Treatment In Children And Adolescents ,Efficacy And Safety Results From ,American College ,Dharma ,Cosentyx ,Shows ,Linically ,Meaningful ,Symptom ,Improvements ,Patients ,Hidradenitis ,Suppurativa ,Pivotal ,Hase ,Trials ,